Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation
- 1 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 193 (7) , 753-766
Abstract
Rationale: Despite the fact that tyrosine kinase inhibitors (TKIs) have been found effective in treating patients harboring activating mutations of epidermal growth factor receptor (EGFR), an acquired secondary mutation, T790M, which lowers the affinity to TKIs, can lead to EGFR TKI resistance after this standard treatment. Objectives: To evaluate the effect of small molecule T315 on EGFR degradation and its therapeutic efficacy in vitro and in vivo. Methods: Lung adenocarcinoma cells were treated with T315, and cell proliferation and apoptotic proportion were determined by the CellTiter 96 AQueous MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay and flow cytometry. The effects of T315 on EGFR mRNA and protein levels, autophosphorylation, ubiquitination, and degradation were evaluated by real-time polymerase chain reaction and Western blot, respectively. Direct targeting of T315 to EGFR was confirmed by the in vitro kinase assay and mass spectrometry. Finally, the preclinical effect of T315 was validated in the murine xenograft model in combination with a second-generation TKI, afatinib. Measurements and Main Results: We identified T315 as a novel, potent small molecule for suppressing cancer cell proliferation in vitro and in vivo. The therapeutic effect was verified after T315 was combined with a second-generation TKI, afatinib, compared with a single drug administration. We found a new mechanism of action, in that T315 appears to directly bind EGFR and triggers EGFR-Y1045 autophosphorylation, whereby its degradation is triggered through the ubiquitin-proteasome pathway. Conclusions: Our evidence suggests that T315 is a novel class of anticancer drug that is able to inhibit the growth of EGFR-TKI–resistant lung adenocarcinoma cells by inducing the degradation of EGFR.Keywords
Funding Information
- National Science Council of the Republic of China (NSC102-2321-B-002-053)
- National Science Council of the Republic of China (NSC102-2325-B-006-016)
- Ministry of Science and Technology Taiwan (MOST 103-2321-B-002-022)
- Ministry of Science and Technology Taiwan (MOST 104-2314-B-002-228-MY3)
- China Medical University (CMU103-RAP-02)
- China Medical University (2325)
- National Taiwan University (CESRP-104R7601-2)
This publication has 46 references indexed in Scilit:
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M MutationsCancer Discovery, 2014
- Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinomaCritical Reviews in Oncology/Hematology, 2013
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant DiseaseJournal of Clinical Oncology, 2013
- Surgery for NSCLC in the era of personalized medicineNature Reviews Clinical Oncology, 2013
- Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancerJournal of Cancer Research and Clinical Oncology, 2012
- The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitorMolecular Cancer Therapeutics, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Inhibition of EGFR Signaling: All Mutations Are Not Created EqualPLOS Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004